The US has set the pace in moving drug development beyond animal testing. The FDA’s 2025 Roadmap was followed by a Year One progress report in April 2026 and a draft NAMs guidance in March 2026. Streamlined nonclinical guidances now cover monoclonal antibodies and oncology biologics. In September 2026, a rule formally recognised NAMs as nonclinical tests. Behind that sit ISTAND, where the first organ-chip qualification package has just been submitted, and the NIH’s Complement-ARIE validation network. In July 2026, China signalled it intends to compete. Its Center for Drug Evaluation (CDE) released draft documents for the “PIONEER Program” (Propel Innovation and Operation of NAMs to Enhance Efficiency in R&D), a five-year pilot to bring New Approach Methodologies (NAMs) such as organoids, organ-chips and in silico models into nonclinical drug evaluation.
China might be starting slightly later than the US, but it could move fast. The program is tied directly to national industrial policy. China clearly intends to shape NAMs regulation to its specific needs and opportunities rather than just copy existing approaches.
I used AI to translate two key documents of the program. Find those translations here:
- Introduction to the Pilot Program for Advancing Research and Application of New Approach Methodologies (NAMs) (“Pioneer Program”)
- Implementation Framework for the Pilot Program for Advancing Research and Application of New Approach Methodologies (NAMs) (“Pioneer Program”) (DRAFT)
Note: these are unofficial AI translations and may contain errors.
What PIONEER is
The CDE presents PIONEER as part of the NMPA’s regulatory science agenda and China’s 15th Five-Year Plan (2026–2030). Its stated aims are to build a platform for cooperation between industry, academia, research institutes and regulators, to advance standardisation of NAMs, and to lay the groundwork for a future regulatory system for validating and using them. The rationale will be familiar. Species differences limit translation, animal studies are slow and costly, and regulators worldwide are pushing the 3Rs.
There are two ways in:
- Product-specific use. A drug developer uses NAMs data to support the registration of a specific drug.
- Joint method validation. A NAM developer validates a method for a defined context of use, with the CDE helping design the protocol. Once validated, the applicant can use the method in that context without validating it again.
A project can start on the first route and add the second later. There is no cap on participant numbers, and applications stay open for five years from launch. Included projects get what the CDE calls “early involvement, timely communication and full-process follow-up” from a dedicated working group.
The drafts list the contexts of use the CDE considers in scope, and they closely track Western priorities including:
- Complementing existing animal data
- Supporting waivers of longer repeat-dose toxicity studies for antibodies
- Specific endpoints such as local tolerance and proarrhythmia
- Advanced therapies and rare-disease drugs, where animal models fall short
- Weight of Evidence contributions to reproductive toxicity and carcinogenicity assessments
How it compares with the US and EU
PIONEER’s defining choice is to put product-level acceptance and method validation behind one door, with the regulator taking a hands-on role in designing the validation.
The US spreads these functions across several bodies and documents:
- Policy direction: the FDA’s 2025 Roadmap.
- General expectations: the March 2026 draft guidance. It centres on context of use, human biological relevance, technical characterisation and fit-for-purpose assessment.
- Product classes: separate guidances cover monoclonal antibodies and oncology biologics.
- Tool qualification: ISTAND qualifies drug development tools for any sponsor to use.
- Validation infrastructure: this sits outside the FDA, in the NIH’s Complement-ARIE VQN, a public–private partnership with more than 40 member organisations.
ISTAND is thorough but slow. As of 2026, it had dozens of projects in development but none fully qualified.
The EU is led by the European Commission’s June 2026 roadmap, which sets 22 actions across 15 domains, including pharmaceuticals. At EMA, developers can use the Innovation Task Force, scientific advice, or formal qualification, whose opinions are published for others to use. EMA also launched a voluntary NAM data submission pilot in September 2026.
| China: PIONEER (draft) | US: FDA and NIH | EU: EC and EMA | |
| Policy framework | 15th Five-Year Plan | FDA Roadmap (2025) | EC Roadmap (2026) |
| Published evidentiary guidance | Not yet | Draft NAMs guidance (2026) | 3Rs and qualification guidance |
| Product and method routes | One program, two scenarios | IND review and ISTAND, separately | Scientific advice and qualification, separately |
| Who designs validation | CDE jointly with applicant | Developer; VQN separately | Developer, with EMA reviewing |
| Who can rely on a validated method | The applicant (as drafted) | Any sponsor, within context of use | Any developer, within published conditions |
There are two clear gaps. PIONEER has no published evidentiary standard yet. And as drafted, a validated method benefits only the applicant, whereas ISTAND and EMA qualification exist to create tools everyone can use. For me, this represents that PIONEER is still in early development and is likely to evolve to match international standards.
Possible impacts
PIONEER is likely to matter more in China than any single Western initiative does in its own market. It is purpose-built to protect China from being out-competed by international NAMs initiatives and address specific risks to Chinese biotechs.
Primates. Quoted cynomolgus monkey prices in China rose from RMB 15,000 in 2019 to RMB 200,000 by July 2026. Supply is estimated to fall about 10,000 animals a year short of demand, and breeding takes years to catch up. The demand comes from China’s strongest modalities: ADCs, bispecifics and in vivo CAR-T, where a single program can use dozens of animals. For these sponsors, PIONEER’s antibody and advanced-therapy contexts of use offer a route to fewer primate studies and faster first-in-human trials.
Licensing. Chinese drugmakers signed roughly US$136 billion in out-licensing deals in 2025, about a third of global deal value. Most of those assets will be developed globally and filed with the FDA and EMA. A NAMs package that satisfies the CDE but not the FDA is worth less at the deal table. The smart approach is to build to the FDA’s draft guidance first, then use PIONEER to bring the CDE into line with it.
NAM developers. Chinese organoid and organ-chip companies now have a validation route at home, and it promises more regulator involvement than ISTAND has so far delivered. That could help China’s large CRO sector add NAM services to its export business. The applicant-only reuse wording limits that upside. So does US policy scrutiny of Chinese research partners, which may affect how Chinese-generated data are received abroad.
What it means
China is betting it can close the international NAMs gap by moving quicker and staying closer to applicants. Whether that bet pays off will depend on details the drafts leave open: whether validated methods become shared tools or private approvals, whether the CDE publishes clear evidentiary standards, and whether its decisions line up with what the FDA and EMA will accept. The first inclusion list and the final text will tell us a lot. If China gets this right, the next wave of NAMs evidence may come from Shanghai and Suzhou as much as from Boston and Bethesda.
Sources
- CDE, NMPA. Pioneer Program consultation documents, 7 July 2026 (Introduction, Application Guidelines, Implementation Framework).
- FDA: Roadmap to Reducing Animal Testing in Preclinical Safety Studies
- Federal Register: General Considerations for the Use of NAMs in Drug Development (draft guidance)
- Pharmaceutical Technology: What FDA’s NAM guidance means
- IntuitionLabs: Organ-on-a-chip FDA qualification status
- NIH Common Fund: Complement-ARIE VQN
- European Commission: Roadmap towards phasing out animal testing
- EMA: Voluntary NAM data submission pilot
- Leon Liao: China’s biotech boom has a monkey bottleneck
- Seoul Economic Daily: Lab monkey prices surge in China
- SynBioBeta/Bloomberg: Lab monkeys for US$26,000
- Vision Lifesciences: China out-licensing report 2026
No responses yet